Scotiabank analyst Sung Ji Nam maintained a Buy rating on Quanterix (QTRX – Research Report) today and set a price target of $32.00. The company’s shares closed yesterday at $16.51.
According to TipRanks, Ji Nam is an analyst with an average return of -4.4% and a 44.39% success rate. Ji Nam covers the Healthcare sector, focusing on stocks such as Quanterix, Adaptive Biotechnologies, and Pacific Biosciences.
Currently, the analyst consensus on Quanterix is a Strong Buy with an average price target of $29.33, which is a 77.65% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $25.00 price target.
The company has a one-year high of $29.70 and a one-year low of $14.26. Currently, Quanterix has an average volume of 395.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Quanterix (QTRX) Company Description:
Quanterix Corp. is a life sciences company, which develops ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its Single Molecule Array (Simoa) technology platform uses single molecule measurements to access previously undetectable proteins. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Lexington, MA.
Read More on QTRX:
